February 1, 2024
Daiichi Sankyo said on January 31 that it has filed an application in Japan seeking an additional indication for its blood cancer agent Ezharmia (valemetostat tosilate) for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...read more